Lexeo Therapeutics is a clinical stage genetic medicine company engaged in transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Co.'s primary cardiovascular product candidate, LX2006, for the treatment of patients with Friedreich's ataxia cardiomyopathy. Co.'s second cardiovascular product candidate, LX2020, for the treatment of arrhythmogenic cardiomyopathy. Co.'s main Alzheimer's disease product candidate, LX1001, for the treatment of APOE4 homozygous patients with Alzheimer's disease. We show 5 historical shares outstanding datapoints in our LXEO shares outstanding history coverage, used to compute LXEO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LXEO market cap history over the course of time is important for investors
interested in comparing LXEO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LXEO versus a peer is one thing; comparing
LXEO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LXEO can fluctuate over the course of history.
With this page we aim to empower investors researching LXEO by allowing them to research the LXEO market cap history. |
Free LXEO Email Alerts:
Video: The Importance of Market Cap
